The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial)

Abstract : The 21-gene Recurrence Score (RS) result predicts outcome and chemotherapy benefit in node-negative and node-positive (N+), estrogen receptor-positive (ER+) patients treated with endocrine therapy. The purpose of this study was to evaluate the prognostic impact of RS results in N+, hormone receptor-positive (HR+) patients treated with adjuvant chemotherapy (6 cycles of FEC100 vs. 3 cycles of FEC100 followed by 3 cycles of docetaxel 100 mg/m2) plus endocrine therapy (ET) in the PACS-01 trial (J Clin Oncol 2006;24:5664-5671).
Document type :
Journal articles
Complete list of metadatas

https://hal.archives-ouvertes.fr/hal-01927081
Contributor : Mouniati Colo <>
Submitted on : Monday, November 19, 2018 - 3:56:56 PM
Last modification on : Thursday, February 7, 2019 - 5:55:11 PM

Links full text

Identifiers

Citation

Frédérique Penault-Llorca, Thomas Filleron, Bernard Asselain, Frederick Baehner, Pierre Fumoleau, et al.. The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial). BMC Cancer, BioMed Central, 2018, 18 (1), pp.526. ⟨10.1186/s12885-018-4331-8⟩. ⟨hal-01927081⟩

Share

Metrics

Record views

54